US 11,701,328 B2
Phosphoserine containing compositions for immune tolerance induction
Sathy Balu-Iyer, Amherst, NY (US); Richard Bankert, Eden, NY (US); Radha Ramakrishnan, Plainsboro, NJ (US); Robert Dingman, Henrietta, NY (US); Vandana Iyer, Amherst, NY (US); Jennifer Schneider, Boston, MA (US); Fiona Yau Glassman, Central Islip, NY (US); and Nhan Hanh Nguyen, Amherst, NY (US)
Assigned to The Research Foundation for The State University of New York, Amherst, NY (US)
Filed by The Research Foundation for The State University of New York, Buffalo, NY (US)
Filed on Mar. 19, 2020, as Appl. No. 16/823,912.
Application 16/823,912 is a continuation of application No. 15/480,149, filed on Apr. 5, 2017, granted, now 10,617,640.
Application 15/480,149 is a continuation in part of application No. 14/349,862, granted, now 10,064,922, issued on Sep. 4, 2018, previously published as PCT/US2012/059223, filed on Oct. 8, 2012.
Application 15/480,149 is a continuation in part of application No. 13/382,684, abandoned, previously published as PCT/US2010/041196, filed on Jul. 7, 2010.
Claims priority of provisional application 62/318,375, filed on Apr. 5, 2016.
Claims priority of provisional application 61/607,195, filed on Mar. 6, 2012.
Claims priority of provisional application 61/223,521, filed on Jul. 7, 2009.
Prior Publication US 2020/0222322 A1, Jul. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 9/127 (2006.01); A61K 31/436 (2006.01); A61K 38/47 (2006.01); A61K 38/39 (2006.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 38/38 (2006.01); A61K 31/203 (2006.01)
CPC A61K 9/127 (2013.01) [A61K 31/203 (2013.01); A61K 31/436 (2013.01); A61K 38/168 (2013.01); A61K 38/1709 (2013.01); A61K 38/38 (2013.01); A61K 38/39 (2013.01); A61K 38/47 (2013.01); C12Y 302/0102 (2013.01)] 7 Claims
 
1. A method for inducing immune tolerance to a target antigen in an individual comprising:
a) providing to the individual a first regimen of multiple administrations of a first composition comprising liposomes, wherein the liposomes comprise phosphatidylcholine (PC) and lyso-phosphatidylserine (lyso-PS), wherein the ratio of PC to lyso-PS is from 90:10 to 60:40, and wherein the liposomes are complexed to a target antigen; and
b) while continuing the first regimen, providing to the individual a second regimen of one or more administrations of a second composition comprising the antigen free of liposomes.